Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis
Multidisciplinary Respiratory Medicine · 03.08.2019 · 14
DOI: 10.4081/mrm.2019.26 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Multidisciplinary Respiratory Medicine, online erschienen am 03.08.2019. Verfasst von Paola Rogliani und 4 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Oral methylxanthines are effective drugs for the treatment of chronic obstructive respiratory disorders. The novel methylxanthine doxofylline, that has bronchodilator and anti-inflammatory activities, is not affected by the major drawback of theophylline. Nowadays large-scale quantitative synthesis comparing the efficacy and safety profile of doxofylline vs. theophylline in the treatment of asthma is still lacking. Therefore, we performed a quantitative synthesis to compare the efficacy/safety profile of doxofylline and theophylline in asthma.
Methods
A pairwise and network meta-analyses were performed to assess the impact of doxofylline vs. theophylline and placebo on the change in asthma events, risk of adverse events (AEs), forced expiratory volume in 1 s (FEV1), and salbutamol use.
Results
Data obtained from 696 asthmatic patients were extracted from 4 randomized controlled trials published between 2015 and 2018. Doxofylline was significantly (P < 0.05) more effective than theophylline in reducing the daily asthma events (mean difference − 0.14, 95%CI -0.27 – 0.00) and risk of AEs (relative risk 0.76, 95%CI 0.59–0.99). Doxofylline was as effective as theophylline in improving FEV1, and a trend of superiority (P = 0.058) was detected for doxofylline over theophylline with respect to the reduction in the use of salbutamol as rescue medication. The rank of effectiveness was doxofylline>theophylline> > placebo, and the rank of safety was placebo>doxofylline> > theophylline.
Conclusions
Doxofylline is an effective and safe methylxanthine for the treatment of asthma, with an efficacy/ safety profile greater than that of theophylline.
Trial registration
Meta-analysis registration: CRD42019119849.
Zitieren
APA
Rogliani, P., Calzetta, L., Ora, J., Cazzola, M., & Matera, M. G. (2019). Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. Multidisciplinary Respiratory Medicine, 14. https://doi.org/10.4081/mrm.2019.26
Vancouver
Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG. Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. Multidisciplinary Respiratory Medicine. 2019;14. doi:10.4081/mrm.2019.26
BibTeX
@article{Rogliani2019,
author = {Rogliani, Paola and Calzetta, Luigino and Ora, Josuel and Cazzola, Mario and Matera, Maria Gabriella},
title = {Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis},
journal = {Multidisciplinary Respiratory Medicine},
year = {2019},
volume = {14},
doi = {10.4081/mrm.2019.26}
}
EUVIMED